Thwarting high-risk prostate cancer: The right treatments for the right patients

European Urology

Volumn 61, Issue 6, 2012, Pages 1107-1109

  Cooperberg, Matthew R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER MORTALITY; CANCER RISK; EARLY DIAGNOSIS; HIGH RISK POPULATION; HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 84860295229     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.03.037     Document Type: Editorial

References (14)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. P.J. Bastian, S.A. Boorjian, and A. Bossi High-risk prostate cancer: from definition to contemporary management Eur Urol 61 2012 1096 1106
3. J.A. Mitchell, M.R. Cooperberg, and E.P. Elkin Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE J Urol 173 2005 1126 1131 (Pubitemid 40380517)
4. M.R. Cooperberg, J. Cowan, J.M. Broering, and P.R. Carroll High-risk prostate cancer in the United States, 1990-2007 World J Urol 26 2008 211 218
5. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis J Natl Cancer Inst 101 2009 878 887
6. S.K. Bechis, P.R. Carroll, and M.R. Cooperberg Impact of age at diagnosis on prostate cancer treatment and survival J Clin Oncol 29 2011 235 241
7. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Outcomes of localized prostate cancer following conservative management JAMA 302 2009 1202 1209
8. A. Konski, W. Speier, A. Hanlon, J.R. Beck, and A. Pollack Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol 25 2007 3603 3608 (Pubitemid 47372597)
9. M.E. Nielsen, D.V. Makarov, E. Humphreys, L. Mangold, A.W. Partin, and P.C. Walsh Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion - "nadir + 2"? Urology 72 2008 389 393 discussion 394-5
10. G. Arcangeli, L. Strigari, and S. Arcangeli Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer Int J Radiat Oncol Biol Phys 75 2009 975 982
11. M.J. Zelefsky, J.A. Eastham, and A.M. Cronin Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix J Clin Oncol 28 2010 1508 1513
12. M.R. Cooperberg, A.J. Vickers, J.M. Broering, P.R. Carroll for the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Investigators Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer Cancer 116 2010 5226 5234
13. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
14. A.S. Kibel, J.P. Ciezki, and E.A. Klein Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era J Urol 187 2012 1259 1265